WHO ICTRP trial
A Study to evaluate the efficacy and safety of dapirolizumab pegol in study…
JPRN-jRCT2071220073 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2071220073 |
|---|---|
| Public title | A Study to evaluate the efficacy and safety of dapirolizumab pegol in study participants with moderately to severely active systemic lupus erythematosus |
| Scientific title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of dapirolizumab pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus - SL0044 PHOENYCS FLY |
| Primary sponsor | Matano Mizuho |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Austria;Japan;Belgium;Japan;Canada;Japan;China;Japan;Denmark;Japan;France;Japan;Germany;Japan;Greece;Japan;Italy;Japan;Poland;Japan;Portugal;Japan;Serbia;Japan;Spain;Japan;South… |
| Conditions | Systemic lupus erythematosus (SLE) |
| Interventions | Study participants will receive dapirolizumab pegol calculated per body weight at pre-specified timepoints. Study participants will receive placebo at pre-specified timepoint. |
| Registration date | Nov 25, 2022 |
| Target size | 40 |
| Secondary IDs | 2019-003407-35 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: